"Specjalistyczne Centrum Gastrologii GASTROMED swoją działalność rozpoczęło w maju 2006 roku. Jest owocem wieloletniej pracy zespołu doświadczonych specjalistów w zakresie gastroenterologii, proktologii, radiologii i anestezjologii. Dbamy o nieustanny rozwój, uczestniczymy w licznych kursach i szkoleniach, podnosimy swoje kwalifikacje, aby móc leczyć według światowych standardów. Zajmujemy się diagnostyką i leczeniem chorób przewodu pokarmowego u dorosłych i dzieci. Poza tradycyjnymi badaniami diagnostycznymi stosujemy innowacyjne rozwiązania tj. kapsułka endoskopowa i gastroskopia bezstresowa. Wychodząc naprzeciw oczekiwaniom pacjenta oferujemy możliwość wykonania badań w znieczuleniu ogólnym."

During the past decade, Gastromed Kralisz Romatowski Stachurska Sp. j. conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 4 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gastromed Kralisz Romatowski Stachurska Sp. j." #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Arena Pharmaceuticals" with 2 trials sponsored, "Janssen Scientific Affairs, LLC" with 1 trials sponsored, "Janssen-Cilag Ltd." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gastromed Kralisz Romatowski Stachurska Sp. j." #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Gastromed Kralisz Romatowski Stachurska Sp. j." are "Ulcerative Colitis" (4 trials), "Crohn Disease" (3 trials), "Colitis, Ulcerative" (1 trials), "Fistulizing Crohns Disease" (1 trials) and "Perianal Crohns Disease" (1 trials). Many other conditions were trialed in "Gastromed Kralisz Romatowski Stachurska Sp. j." in a lesser frequency.

Most popular intervention types in "Gastromed Kralisz Romatowski Stachurska Sp. j." are "Drug" (8 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Etrasimod" (3 trials), "Guselkumab" (2 trials), "Guselkumab Dose 1" (2 trials) and "Guselkumab Dose 2" (2 trials). Other intervention names were less common.

The vast majority of trials in "Gastromed Kralisz Romatowski Stachurska Sp. j." are 9 trials for "All" genders.

Currently, there are NaN active trials in "Gastromed Kralisz Romatowski Stachurska Sp. j.". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Gastromed Kralisz Romatowski Stachurska Sp. j., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Gastromed Kralisz Romatowski Stachurska Sp. j., 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".